View on market: Stay Cautious, be with quality business:

Asian stocks climbed Monday as traders digested the outcome of Japan’s election and fresh all-time highs for U.S. shares. The yen weakened and a dollar gauge was steady. Equities jumped more than 1% in Japan, where Prime Minister Fumio Kishida’s Liberal Democratic Party preserved its outright majority, avoiding worst-case scenarios and smoothing the way for fiscal stimulus. Australia and South Korea pushed higher. U.S. futures were in the green following records for the S&P 500 and Nasdaq 100 on optimism about corporate earnings. The Singapore-traded SGX Nifty, an early indicator of India’s Nifty 50 Index’s performance, rose 0.20 to 17,785.50, as of 8:00 a.m.

Economic Calender:

  • INR:  Nikkei Markit Manufacturing PMI (Oct) on 1st November, 2021.
  • INR: Trade Balance (Oct) on 2nd November, 2021.
  • USD: ISM Manufacturing PMI (Oct) on 01st November, 2021.
  • USD: Fed Interest Rate Decision on 03rd November, 2021.

Earnings: HDFC, Tata Motors, IRCTC, Indian Railway Finance Corporation, Aditya Birla Capital, Bayer Cropscience, Allcargo Logistics, Bajaj Consumer Care, Carborundum Universal, Chambal Fertilisers & Chemicals, Graphite India, IndInfravit Trust, Lux Industries, Man Infraconstruction, Nilkamal, The Phoenix Mills, Poly Medicure, Punjab & Sind Bank, Relaxo Footwears, Rupa & Company, Shipping Corporation of India, Sun Pharma Advanced Research Company, Star Cement, Venky’s (India), VRL Logistics, Whirlpool Of India& Company, Shipping Corporation of India, Sequent Scientific, Sun Pharma Advanced Research Company, Star Cement, Venky’s (India), VRL Logistics, Whirlpool Of India.


BPCL Q2FY22 (Standalone, QoQ): Revenues up 15% at Rs 81,536.67 crore Vs Rs 70,921.28 crore. Net profit up 79.4% at Rs 2,694.1 crore Vs Rs 1,501.65 crore.  Ebitda up 37.7% at Rs 4,477.71 crore Vs Rs 3,252.74 crore. Margins at 5.5% vs 4.6%. Declared an interim dividend of Rs 5 per share.

Vedanta Q2FY22 (Consolidated, QoQ): Revenue up 7% at Rs 30,401 crore Vs Rs 28,412 crore. Net profit up 9.3% at Rs 4,615 crore Vs Rs 4,224 crore .Ebitda up 4.9% at Rs 10,363 crore Vs Rs 9,871 crore. Margins at 34.1% vs 34.7%.

Steel Authority of India Q2FY22 (Consolidated, YoY): Revenue up 59% at Rs 26,828.01 crore Vs Rs 16,925.49 crore Net profit up 8.94 times at Rs 4,338.75 crore Vs Rs 436.52 crore Ebitda up 2.70 times at Rs 7,033.85 crore Vs Rs 1,902.23 crore Margin at 26.2% Vs 11.2% Declared an interim dividend of Rs 4 per share.

Shree Cement Q2FY22 (Standalone, QoQ): Revenues down 7.1% at Rs 3,205.87 crore Vs Rs 3,449.5 crore. Net profit down 25% at Rs 577.7 crore Vs Rs 661.7 crore. Ebitda down 16.9% at Rs 898.2 crore Vs Rs 1,013.5 crore. Margins at 28% Vs 29.4%

Brokerage Radar:

CLSA ON VEDANTA: Maintain outperform at the price of Rs 303.90 for the target price of Rs 320. Q2 in-line but higher costs likely to be offset by higher metal prices. Both aluminium & oil segments reported strong results. It lifted its cost guidance across segments, but higher metal prices will offset this.

MACQUARIE ON DR REDDY’S: Maintain outperform at the price of Rs 4635.80 for the target price of Rs 5692. Strong comeback on margin front in Q2 after a forgettable Q1. Raise FY22-24 EPS estimates by 6-9% Ex-Sputnik V & Grevlimid, expect co to deliver 14.3% EPS CAGR over FY21-24.

International Markets:

U.S & Europe

Particulars       29th Oct    Chg Chg(%)
Nasdaq 15,498.39 50.27 0.33
Dow 35,819.56 89.05 0.25
FTSE 7,237.57 -11.90 -0.16
CAC 6,830.34 26.12 0.38
DAX 15,688.77 -7.56 -0.05
Dow Fut.* 35,799.00 96.00 0.27

Asian markets:

Particulars   1st Nov    Chg Chg(%)
SGX Nifty 17,785.50 35.50 0.20
Nikkei 29,534.50 641.81 2.22
Straits Times 3,220.04 21.87 0.68
Hang Seng 25,049.45 -327.79 -1.29
Shanghai 3,534.00 13.34 -0.38

ADR Watch:

Particulars     29th Oct Chg Chg(%)
Dr Reddy 61.44 0.37 0.61
HDFC Bank 71.91 -2.40 -3.23
ICICI Bank 21.15 -0.14 -0.66
Infosys 22.28 -0.28 -1.24
Tata Motor 31.58 -0.46 -1.44
Wipro 8.96 -0.16 -1.75

Commodities & Currency

Particulars Current Price Chg(%)
USD/INR        74.88 -0.04
Brent 83.65 -0.08
Gold 1787.15 0.18
Silver 23.942 -0.03


Particulars         29th Oct         28th Oct
FIIs -5142.63 -3819.51
DIIs 4342.51 836.60

News Update:

Reliance Industries: JioPhone Next will go on sale starting Diwali, November 4 at a price of Rs 6,499, the company said. The phone will be available across the country at Reliance Retail’s network of JioMart Digital retail locations.

Adani Enterprises: The Adani Group has acquired a significant minority stake in Flipkart-owned Cleartrip Pvt., a ticket and hotel booking portal. Through this investment, the Adani Group and the Flipkart Group will benefit from synergies that will deliver superior travel experiences to consumers as the travel industry in India sees a resurgence, the company said.

Dr. Reddy’s Laboratories: Company has launched Ephedrine Sulfate Injection USP, 50 mg/mL, a therapeutic equivalent generic version of Akovaz Injection, 50 mg/mL in the U.S.

Tata Consumer Products: To transition its Tata Cha business, a tea café format quick service restaurant chain, to Qmin-Shops operated by a subsidiary of Indian Hotels Company.

Indiamart Intermesh: The company has acquired 7.70% stake in Mynd Solutions for Rs 32.43 crore.

Source: Moneycontrol, Livemint,, Bloomberg, Investing

Disclosure in pursuance of Section 19 of SEBI (RA) Regulation 2014

Elite Wealth Limited does/does not do business with companies covered in its research reports. Investors should be aware that the Elite Wealth Limited may/may not have a conflict of interest that could affect the objectivity of this report. Investors should consider this report as only information in making their investment decision and must exercise their own judgment before making any investment decision.
For analyst certification and other important disclosures, see the Disclosure Appendix, or go to Analysts employed by Elite Wealth Limited are registered/qualified as research analysts with SEBI in India.( SEBI Registration No.: INH100002300)
Disclosure Appendix
Analyst Certification (For Reports)
Israil Khan, Elite Wealth Limited,
The analyst(s) certify that all of the views expressed in this report accurately reflect my/our personal views about the subject company or companies and its or their securities. I/We also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report. Unless otherwise stated, the individuals listed on the cover page of this report are analysts in Elite Wealth Limited.
As to each individual report referenced herein, the primary research analyst(s) named within the report individually certify, with respect to each security or issuer that the analyst covered in the report, that:
(1) all of the views expressed in the report accurately reflect his or her personal views about any and all of the subject securities or issuers; and
(2) no part of any of the research analyst’s compensation was, is, or will be directly or indirectly related to the specific recommendations or views expressed in the report.
For individual analyst certifications, please refer to the disclosure section at the end of the attached individual notes.
Research Excerpts
This note may include excerpts from previously published research. For access to the full reports, including analyst certification and important disclosures, investment thesis, valuation methodology, and risks to rating and price targets, please visit
Company-Specific Disclosures
Important disclosures, including price charts, are available and all Elite Wealth Limited covered companies by visiting, or emailing with your request. Elite Wealth Limited may screen companies based on Strategy, Technical, and Quantitative Research. For important disclosures for these companies, please e-mail
Options related research:
If the information contained herein regards options related research, such information is available only to persons who have received the proper option risk disclosure documents. For a copy of the risk disclosure documents, please contact your Broker’s Representative or visit the OCC’s website at
Other Disclosures
All research reports made available to clients are simultaneously available on our client websites. Not all research content is redistributed, e-mailed or made available to third-party aggregators. For all research reports available on a particular stock, please contact your respective broker’s sales person.
Ownership and material conflicts of interest Disclosure
Elite Wealth Limited policy prohibits its analysts, professionals reporting to analysts from owning securities of any company in the analyst’s area of coverage. Analyst compensation: Analysts are salary based permanent employees of Elite Wealth Limited. Analyst as officer or director: Elite Wealth Limited policy prohibits its analysts, persons reporting to analysts from serving as an officer, director, board member or employee of any company in the analyst’s area of coverage.
Country Specific Disclosures
India – For private circulation only, not for sale.
Legal Entities Disclosures
Mr. Ravinder Parkash Seth is the Managing Director of Elite Wealth Ltd (EWL, henceforth), having its registered office at Casa Picasso, Golf Course Extension, Near Rajesh Pilot Chowk, Radha Swami, Sector-61, Gurgaon-122001 Haryana, is a SEBI registered Research Analyst and is regulated by Securities and Exchange Board of India. Telephone:011-43035555, Facsimile: 011-22795783 and Website:
EWL discloses all material information about itself including its business activity, disciplinary history, the terms and conditions on which it offers research report, details of associates and such other information as is necessary to take an investment decision, including the following:
1. Reports
a) EWL or his associate or his relative has no financial interest in the subject company and the nature of such financial interest;
(b) EWL or its associates or relatives, have no actual/beneficial ownership of one per cent. or more in the securities of the subject company, at the end of the month immediately preceding the date of publication of the research report or date of the public appearance;
(c) EWL or its associate or his relative, has no other material conflict of interest at the time of publication of the research report or at the time of public appearance;
2. Compensation
(a) EWL or its associates have not received any compensation from the subject company in the past twelve months;
(b) EWL or its associates have not managed or co-managed public offering of securities for the subject company in the past twelve months;
(c) EWL or its associates have not received any compensation for investment banking or merchant banking or brokerage services from the subject company in the past twelve months;
(d) EWL or its associates have not received any compensation for products or services other than investment banking or merchant banking or brokerage services from the subject company in the past twelve months;
(e) EWL or its associates have not received any compensation or other benefits from the Subject Company or third party in connection with the research report.
3 In respect of Public Appearances
(a) EWL or its associates have not received any compensation from the subject company in the past twelve months;
(b) The subject company is not now or never a client during twelve months preceding the date of distribution of the research report and the types of services provided by EWL